revis estim grow downward pressur
action reduc estim mitsubishi tanab lower target
price maintain neutral rate also
introduc forecast
invest overview reduc estim reflect greater-than-
expect gener competit legaci product japan drug price
cut estim legaci product account around domest sale
exclud vaccin also expect royalti revenu
inhibitor invokana diabet peak earlier previous assum
due declin oversea sale via johnson johnson sale
radicava al launch us set move
blockbust territori rise
thu allow compani avoid drop profit think mitsubishi
tanab may hold pattern compani expect
launch two promis new product plant-bas vlp vaccin
influenza parkinson diseas
catalysts/risk mitsubishi tanab lack catalyst could see
share-pric gain compani rapidli turn radicava blockbust
expect rise boost earn stage howev see
limit potenti upsid base guidanc sale yoy core op
op event could act potenti catalyst
includ corpor acquisit product licens us market focu
area mitsubishi tanab
valuat base target price ep forecast
previous forward price-to-earnings
valuat metric
chang tp
number share mn
price month
price rel chart measur perform
topix close
spot exchang rate
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
price jun upsid rate neutral target price analyst fumiyoshi sakai
profit tax
issuanc retir stock
net chang cash
number share mn
net incom attribut owner
parent compani
amort intang asset associ product
profit tax
cash equival
amort intang asset associ product
agent improv hepat biliari digest
compani mention price
